News | December 30, 2025
Harbour BioMed teams up with Lannacheng to advance next-generation cancer therapies
Harbour BioMed brings advanced antibody discovery platforms to the table
Harbour BioMed brings advanced antibody discovery platforms to the table
CX-5461 is “the world's first and most advanced G-quadruplex (G4) stabilizer in development
NGD Infection Prevention was formed to scale the delivery of sequence-based transmission detection
Lucid-MS represents a potential breakthrough in the treatment of multiple sclerosis
The approval follows results from the DESTINY-Breast06 phase 3 trial, which showed ENHERTU significantly extended progression-free survival compared to chemotherapy
The primary goal of the collaboration is joint research into trending and next-generation molecules
Lupin has bolstered its diabetes and obesity portfolios by securing an agreement for Bofanglutide, a GLP-1 receptor agonist developed by Gan & Lee Pharmaceuticals
Intas becomes the first and only company in India to offer IVF and gynecology therapies with needle-free injections
Wayrilz represents a new approach to ITP by targeting the disease at its root through multi-immune modulation
CLE, a common form of lupus erythematosus, primarily causes diverse skin lesions
Subscribe To Our Newsletter & Stay Updated
